Biopharma Credit PLC to Issue Dividend of $0.01 (BPCR)

Biopharma Credit PLC (LON:BPCR) declared a dividend on Thursday, December 7th, Upcoming.Co.Uk reports. Shareholders of record on Thursday, December 14th will be paid a dividend of $0.01 per share on Wednesday, January 31st. This represents a yield of 0.93%. The ex-dividend date is Thursday, December 14th. The official announcement can be accessed at this link.

Shares of Biopharma Credit (LON BPCR) traded up GBX 0.02 ($0.00) during trading hours on Wednesday, reaching GBX 1.04 ($0.01). The company’s stock had a trading volume of 35,501 shares, compared to its average volume of 58,769. Biopharma Credit has a 1-year low of GBX 1 ($0.01) and a 1-year high of GBX 1.13 ($0.02).

TRADEMARK VIOLATION NOTICE: “Biopharma Credit PLC to Issue Dividend of $0.01 (BPCR)” was originally reported by Transcript Daily and is the property of of Transcript Daily. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://transcriptdaily.com/2017/12/13/biopharma-credit-plc-to-issue-dividend-of-0-01-bpcr.html.

Biopharma Credit Company Profile

BioPharma Credit Plc is a closed-ended investment company. The Company’s investment objective is to generate long-term shareholder returns, predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The Company may acquire debt assets from a company operating in the life sciences industry or an entity other than a life sciences company, which directly or indirectly holds an interest in royalty rights to certain products, including any investment vehicle or special purpose vehicle.

Receive News & Ratings for Biopharma Credit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharma Credit and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply